Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




TB Sequencing Could Replace Drug Susceptibility Testing

By LabMedica International staff writers
Posted on 08 Oct 2018
Tuberculosis (TB) is the most deadly infectious disease worldwide, causing 1.6 million deaths in 2017. More...
Drug resistance is a particularly challenging and growing problem: as in 2017, it was estimated that 558,000 new cases of TB were resistant to rifampicin, the most effective first-line drug, and globally, just over half of patients with multi-drug resistant TB are successfully treated.

An advantage of using sequencing is that both susceptibility and resistance testing can be done in one assay. Currently, drug susceptibility testing is performed using culture-based methods, which can be time consuming. Although rapid polymerase chain reaction (PCR)-based drug resistance tests have been developed, but are not the same as if a resistance mutation is not identified, drug susceptibility cannot be inferred.

A large consortium of scientists working with those at the Nuffield Department of Medicine (Oxford University, UK) obtained whole-genome sequences and associated phenotypes of resistance or susceptibility to the first-line anti-tuberculosis drugs isoniazid, rifampin, ethambutol, and pyrazinamide for isolates from 16 countries across six continents. For each isolate, mutations associated with drug resistance and drug susceptibility were identified across nine genes, and individual phenotypes were predicted unless mutations of unknown association were also present.

Isolates were sequenced on Illumina platforms. Phenotypic drug-susceptibility testing was performed locally with the use of an MGIT 960 system, by culture on suitable medium or by microscopic-observation drug-susceptibility (MODS) assay, with method-specific critical concentrations.

The scientists analyzed a total of 10,209 isolates. The largest proportion of phenotypes was predicted for rifampin 9,660/10,130 (95.4%) and the smallest was predicted for ethambutol 8,794/9,794 (89.8%). Resistance to isoniazid, rifampin, ethambutol, and pyrazinamide was correctly predicted with 97.1%, 97.5%, 94.6%, and 91.3% sensitivity, respectively, and susceptibility to these drugs was correctly predicted with 99.0%, 98.8%, 93.6%, and 96.8% specificity. Of the 7,516 isolates with complete phenotypic drug-susceptibility profiles, 5,865 (78.0%) had complete genotypic predictions, among which 5,250 profiles (89.5%) were correctly predicted. Among the 4,037 phenotypic profiles that were predicted to be pansusceptible, 3,952 (97.9%) were correctly predicted.

Timothy Walker, MD, D Phil, a clinical lecturer and co-author of the study, said, “Molecular tests to predict drug susceptibility are potentially a paradigm shift. The data has already had an impact and I imagine other public health agencies will follow suit as well. With a portable platform, the goal of delivering individualized therapy to the bedside anywhere in the world becomes more realistic. It's no longer a pipe dream.” The study was published on September 26, 2018, in the journal The New England Journal of Medicine.

Related Links:
Nuffield Department of Medicine


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.